Table 4.

Comparing Capreomycin, Amikacin, and Kanamycin (Susceptible Only)

DrugEvents/TotalEvents/TotalPairs, No.Odds Ratio
(95% CI)
Risk Difference
(95% CI)a
Amikacin vs kanamycinAmikacinKanamycin
  Cured1302/13942192/252313942.0 (1.5–2.5)0.06 (.04–.08)
  Died250/1644435/295816430.7 (.6–.8)−0.02 (−.04 to .01)
Comparison in fluoroquinolone-resistant subgroup
  Cured168/186178/2131722.0 (1.0–3.8)0.08 (.01–.15)
  Died43/22939/2522160.8 (.5–1.3)0.02 (−.05 to .10)
Capreomycin vs amikacinCapreomycinAmikacin
  Cured821/9381302/13949380.3 (.2–.4)−0.09 (−.11 to −.06)
  Died176/1114250/164411131.7 (1.3–2.2)0.05 (.02–.08)
Comparison in fluoroquinolone-resistant subgroup
  Cured118/168168/1861600.3 (.2–.5)−0.20 (−.30 to −.11)
  Died52/22043/2292161.8 (1.1–2.9)0.04 (−.04 to .12)
Capreomycin vs kanamycinCapreomycinKanamycin
  Cured821/9382192/25239380.8 (.6–1.0)−0.02 (−.05 to .01)
  Died176/1114435/295811140.8 (.6–1.0)0.01 (−.02 to .04)
Comparison in fluoroquinolone-resistant subgroup
  Cured 118/168178/2131680.8 (.5–1.2)−0.05 (−.15 to .05)
  Died52/22039/2522201.0 (.7–1.6)0.12 (.05–.20)
DrugEvents/TotalEvents/TotalPairs, No.Odds Ratio
(95% CI)
Risk Difference
(95% CI)a
Amikacin vs kanamycinAmikacinKanamycin
  Cured1302/13942192/252313942.0 (1.5–2.5)0.06 (.04–.08)
  Died250/1644435/295816430.7 (.6–.8)−0.02 (−.04 to .01)
Comparison in fluoroquinolone-resistant subgroup
  Cured168/186178/2131722.0 (1.0–3.8)0.08 (.01–.15)
  Died43/22939/2522160.8 (.5–1.3)0.02 (−.05 to .10)
Capreomycin vs amikacinCapreomycinAmikacin
  Cured821/9381302/13949380.3 (.2–.4)−0.09 (−.11 to −.06)
  Died176/1114250/164411131.7 (1.3–2.2)0.05 (.02–.08)
Comparison in fluoroquinolone-resistant subgroup
  Cured118/168168/1861600.3 (.2–.5)−0.20 (−.30 to −.11)
  Died52/22043/2292161.8 (1.1–2.9)0.04 (−.04 to .12)
Capreomycin vs kanamycinCapreomycinKanamycin
  Cured821/9382192/25239380.8 (.6–1.0)−0.02 (−.05 to .01)
  Died176/1114435/295811140.8 (.6–1.0)0.01 (−.02 to .04)
Comparison in fluoroquinolone-resistant subgroup
  Cured 118/168178/2131680.8 (.5–1.2)−0.05 (−.15 to .05)
  Died52/22039/2522201.0 (.7–1.6)0.12 (.05–.20)

Excluded: 857 who received ≥ 2 injectables for no clear reason. Included: 613 no injectables, 10 307 who received only 1 injectable, and 253 who were switched to an effective second-line injectable drug based on drug susceptibility test results.

Values in bold are statistically significant (P < .05), meaning that 95% CI do not include 1.0 for odds ratios, or do not include 0 for risk differences.

Abbreviation: CI, confidence interval.

aEffect adjusted for age, sex, human immunodeficiency virus status, acid-fast smear microscopy results, cavities on chest radiograph, prior treatment with first- and second-line tuberculosis drugs, and resistance to fluoroquinolones or second-line injectables, and number of possibly effective drugs in the initial phase. In all models, odds ratios were estimated with random-effects model (intercept and slope), but risk differences were estimated with fixed-effects models as random-effects models would not converge.

Table 4.

Comparing Capreomycin, Amikacin, and Kanamycin (Susceptible Only)

DrugEvents/TotalEvents/TotalPairs, No.Odds Ratio
(95% CI)
Risk Difference
(95% CI)a
Amikacin vs kanamycinAmikacinKanamycin
  Cured1302/13942192/252313942.0 (1.5–2.5)0.06 (.04–.08)
  Died250/1644435/295816430.7 (.6–.8)−0.02 (−.04 to .01)
Comparison in fluoroquinolone-resistant subgroup
  Cured168/186178/2131722.0 (1.0–3.8)0.08 (.01–.15)
  Died43/22939/2522160.8 (.5–1.3)0.02 (−.05 to .10)
Capreomycin vs amikacinCapreomycinAmikacin
  Cured821/9381302/13949380.3 (.2–.4)−0.09 (−.11 to −.06)
  Died176/1114250/164411131.7 (1.3–2.2)0.05 (.02–.08)
Comparison in fluoroquinolone-resistant subgroup
  Cured118/168168/1861600.3 (.2–.5)−0.20 (−.30 to −.11)
  Died52/22043/2292161.8 (1.1–2.9)0.04 (−.04 to .12)
Capreomycin vs kanamycinCapreomycinKanamycin
  Cured821/9382192/25239380.8 (.6–1.0)−0.02 (−.05 to .01)
  Died176/1114435/295811140.8 (.6–1.0)0.01 (−.02 to .04)
Comparison in fluoroquinolone-resistant subgroup
  Cured 118/168178/2131680.8 (.5–1.2)−0.05 (−.15 to .05)
  Died52/22039/2522201.0 (.7–1.6)0.12 (.05–.20)
DrugEvents/TotalEvents/TotalPairs, No.Odds Ratio
(95% CI)
Risk Difference
(95% CI)a
Amikacin vs kanamycinAmikacinKanamycin
  Cured1302/13942192/252313942.0 (1.5–2.5)0.06 (.04–.08)
  Died250/1644435/295816430.7 (.6–.8)−0.02 (−.04 to .01)
Comparison in fluoroquinolone-resistant subgroup
  Cured168/186178/2131722.0 (1.0–3.8)0.08 (.01–.15)
  Died43/22939/2522160.8 (.5–1.3)0.02 (−.05 to .10)
Capreomycin vs amikacinCapreomycinAmikacin
  Cured821/9381302/13949380.3 (.2–.4)−0.09 (−.11 to −.06)
  Died176/1114250/164411131.7 (1.3–2.2)0.05 (.02–.08)
Comparison in fluoroquinolone-resistant subgroup
  Cured118/168168/1861600.3 (.2–.5)−0.20 (−.30 to −.11)
  Died52/22043/2292161.8 (1.1–2.9)0.04 (−.04 to .12)
Capreomycin vs kanamycinCapreomycinKanamycin
  Cured821/9382192/25239380.8 (.6–1.0)−0.02 (−.05 to .01)
  Died176/1114435/295811140.8 (.6–1.0)0.01 (−.02 to .04)
Comparison in fluoroquinolone-resistant subgroup
  Cured 118/168178/2131680.8 (.5–1.2)−0.05 (−.15 to .05)
  Died52/22039/2522201.0 (.7–1.6)0.12 (.05–.20)

Excluded: 857 who received ≥ 2 injectables for no clear reason. Included: 613 no injectables, 10 307 who received only 1 injectable, and 253 who were switched to an effective second-line injectable drug based on drug susceptibility test results.

Values in bold are statistically significant (P < .05), meaning that 95% CI do not include 1.0 for odds ratios, or do not include 0 for risk differences.

Abbreviation: CI, confidence interval.

aEffect adjusted for age, sex, human immunodeficiency virus status, acid-fast smear microscopy results, cavities on chest radiograph, prior treatment with first- and second-line tuberculosis drugs, and resistance to fluoroquinolones or second-line injectables, and number of possibly effective drugs in the initial phase. In all models, odds ratios were estimated with random-effects model (intercept and slope), but risk differences were estimated with fixed-effects models as random-effects models would not converge.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close